Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH), a condition marked by dangerously low blood sugar following weight-loss surgery.In the Phase 2b trial, a 90 mg once-daily dose of avexitide—now being evaluated in the Phase 3 LUCIDITY trial—achieved a 64% reduction in the r ...